Can-Fite BioPharma Phase IIb Study with CF101 as a Monotherapy for Rheumatoid Arthritis Met Primary Endpoints

Can-Fite BioPharma

announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist. The study entailed 2 arms, a placebo and a CF101 1 mg treated group, in which CF101 was administered orally twice-daily as a monotherapy for 12 weeks to patients with RA.  Only patients with elevated baseline expression levels of the biomarker A3AR were enrolled in the study.